Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"It is good that they want world-wide rights and first refusal for other GI disorders, and medically this does include the mouth and therefore OM."

"Other GI disorders", not "all other GI disorders".
Here's what they actually said:
"a Right of First Negotiation for rights to Brilacidin in other Gastrointestinal (GI) indications."

No reference is made to Oral Mucositis in the body of the PR, only in the "About Innovation Pharmaceuticals" section. What GOOD reason could they possibly have to leave a specific reference to OM out of their announcement that there is a Right of First Negotiation in this term sheet? If it was actually one of the Gastrointestinal (GI) indications to which the RFN applies wouldn't it ADD to the value of the press release to say so?

Was it a fear of providing too much in the way of specific information? (Wouldn't be the first time.)

When has IPIX EVER referred to OM as a Gastrointestinal disorder?

This is NOT what the release says:
"The potential licensee has RFN on all GI indications, which would include OM."

Don't let confirmation bias influence your statements. Your words are often repeated by others.